Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
10/23/2002 | EP1250937A2 Controlled dissolution of active ingredients |
10/23/2002 | EP1250936A1 Use of starch for transdermal applications |
10/23/2002 | EP1250933A1 Vaccines including as an adjuvant high dose type I IFN |
10/23/2002 | EP1250932A1 A stable aqua formulation of interferon, the preparation method and the uses thereof |
10/23/2002 | EP1250927A2 Pharmaceutical composition for topical application comprising nifedipine |
10/23/2002 | EP1250925A2 Nasal spray containing ondansetron hydrochloride |
10/23/2002 | EP1250920A1 Unloaded ion exchange resins for the extended release of active ingredients |
10/23/2002 | EP1250919A1 Gelling, relaxing bath compositions |
10/23/2002 | EP1250916A1 An emulsifying agent without peg and their use for the preparation at room temperature of cosmetic, phaceutical and dermatological compositions |
10/23/2002 | EP1250849A1 Morinda citrifolia (Noni) enhanced animal food product |
10/23/2002 | EP1250434A2 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
10/23/2002 | EP1250361A2 Degradable poly(vinyl alcohol) hydrogels |
10/23/2002 | EP1250359A1 Chitosan condensation products, their preparation and their uses |
10/23/2002 | EP1250355A1 Chimeric prostate-homing peptides with pro-apoptotic activity |
10/23/2002 | EP1250343A1 Azalide antibiotic compositions |
10/23/2002 | EP1250166A1 Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia |
10/23/2002 | EP1250161A2 Polymer blends as biodegradable matrices for preparing biocomposites |
10/23/2002 | EP1250156A1 Method for nucleic acid transfection of cells |
10/23/2002 | EP1250154A2 G-csf conjugates |
10/23/2002 | EP1250153A2 TREATMENT OF i C. DIFFICILE /i TOXIN B ASSOCIATED CONDITIONS |
10/23/2002 | EP1250152A1 Hyaluronic acid in the treatment of cancer |
10/23/2002 | EP1250151A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis |
10/23/2002 | EP1250149A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
10/23/2002 | EP1250143A2 Reduction in bacterial colonization by administering bacteriophage compositions |
10/23/2002 | EP1250142A1 Multivalent electron active compositions and methods of making and using same |
10/23/2002 | EP1250138A1 Fulvestrant formulation |
10/23/2002 | EP1250134A1 Compositions for the prevention of diaper dermatitis |
10/23/2002 | EP1250133A1 Ophthalmic anti-allergy compositions suitable for use with contact lenses |
10/23/2002 | EP1250132A1 Ibuprofen containing active agent preparation |
10/23/2002 | EP1250130A1 Propofol formulation with enhanced microbial inhibition |
10/23/2002 | EP1250126A2 Transepithelial delivery of glp-1 derivatives |
10/23/2002 | EP1250125A2 Pharmaceutical compositions comprising terbinafine |
10/23/2002 | EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application |
10/23/2002 | EP1250094A1 Tunable indocyanine dyes for biomedical applications |
10/23/2002 | EP1250056A1 Composition for intestinal delivery |
10/23/2002 | EP1250055A1 Immune modulation with death receptor-induced apoptosis |
10/23/2002 | EP1250053A2 Method for produce sanitation using bacteriophages |
10/23/2002 | EP1250050A2 Method and device for sanitation using bacteriophages |
10/23/2002 | EP1250046A1 Improved topical drug delivery composition and method |
10/23/2002 | EP1144009B1 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
10/23/2002 | EP1107734B1 Oral liquid mucoadhesive compositions |
10/23/2002 | EP0994727B1 Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles |
10/23/2002 | EP0977626B1 Composition based on alkylpolyglycosides and fatty alcohols, and uses thereof |
10/23/2002 | EP0885014B1 Pharmaceutical compositions containing buffered ortho ester polymers |
10/23/2002 | EP0844269B1 Block copolymer having functional groups at both ends |
10/23/2002 | EP0822217B1 Heterotelechelic block copolymers and process for producing the same |
10/23/2002 | EP0804241B1 Utilization of ethoxylated fatty acid esters as self-emulsifiable compounds |
10/23/2002 | EP0775173B1 Starch-bound cellular matrix |
10/23/2002 | CN1376166A Peptide that lower blood glucose levels |
10/23/2002 | CN1376164A Gcsf缀合物 Gcsf conjugates |
10/23/2002 | CN1376148A Rate-controlled particles |
10/23/2002 | CN1376146A Solid-state form of celecoxil having enhanced bioavailability |
10/23/2002 | CN1376074A Antibody-dye conjugates for binding to target structures of angiogenesis in order to introperatively depict tumor peripheries |
10/23/2002 | CN1376073A Method of expressing antigen on the surface of an antigen-presenting cell by photochemical internalisation |
10/23/2002 | CN1376071A Anti cancer agent and method of treatment of cancer |
10/23/2002 | CN1376065A Compositions having improved stability |
10/23/2002 | CN1376059A Hydrodynamically balancing oral drug delivery system |
10/23/2002 | CN1376057A Anti-virus composition |
10/23/2002 | CN1376056A Liposome-entrapped DNA oral vaccines |
10/23/2002 | CN1376055A Aerosol ointment compositions and method of manufacture |
10/23/2002 | CN1376054A Topcial suspension formulations containing ciprofloxacin and dexa methasone |
10/23/2002 | CN1376043A Drug delivery of phase changing formulation |
10/23/2002 | CN1375453A Heterogeneous silica as carrier material |
10/23/2002 | CN1092995C Oil-in-water emulsifiers |
10/23/2002 | CN1092990C Modulation of cell proliferation and wound healing |
10/23/2002 | CN1092988C Thermally stabilized contrast agent |
10/23/2002 | CN1092987C Delivery of therapeutic agents to receptors using polysaccharides |
10/23/2002 | CN1092986C CoA oral preparation for reducing blood fat and its preparation method and application |
10/23/2002 | CN1092960C Pharmaceutical composition comprising proteinase inhibitor and monoglyceride |
10/23/2002 | CN1092959C Pharmaceutical composition contg. tiagabine or receptive salt and process for its preparation |
10/23/2002 | CN1092956C Sustained release drug formulation containing a tramadol salt |
10/23/2002 | CN1092954C Ophthalamic compositions containing cyclotextrins and quatemary ammonium compound |
10/23/2002 | CA2383149A1 Process for partially reducing or eliminating the symptoms associated with the release of histamine in the body |
10/23/2002 | CA2383115A1 Use of an effective amount of at least one ion chelating agent to enhance the tolerance level of sensitive or intolerant skin |
10/22/2002 | WO2001091753A1 Active substance combination containing an opioid having a fentanyl-type structure and ketamine |
10/22/2002 | US6469187 Contaminant reduced marine oil |
10/22/2002 | US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis |
10/22/2002 | US6469069 Propofol composition containing sulfite |
10/22/2002 | US6469066 Treating burns with one or more of acetic acid, vinegar and citric acid for prevention of delayed hyperalgesia |
10/22/2002 | US6469022 By inhibition of the p-glycoprotein efflux pump, a multidrug transporter, in the intestinal mucosa; allowing intracellular accumulation of drug |
10/22/2002 | US6468989 Gel compositions containing metronidazole |
10/22/2002 | US6468986 Composition comprising polynucleotide and polycationic agent which exhibits net positive electrical charge at physiological ph, and is capable of mediating entry of polynucleotides into cell |
10/22/2002 | US6468981 Compound comprising steroid moiety which binds to androgen receptor covalently linked to polycationic salt complexed with nucleic acid capable of therapeutically modifying or revealing presence of androgen receptor-containing cell |
10/22/2002 | US6468968 Comprising a cyclosporin in a carrier medium of a fatty acid triglyceride and a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester; biavailability; side-effect reductions |
10/22/2002 | US6468962 Nutritional intervention composition for enhancing and extending satiety |
10/22/2002 | US6468961 Gel composition and methods |
10/22/2002 | US6468960 Therapeutic compositions and methods for enhancing angiogenesis |
10/22/2002 | US6468798 Liposome-nucleic acid complexes are prepared then delivered via aerosol to the lung airway; for transforming pulmonary cells and treating lung diseases |
10/22/2002 | US6468557 Method for treating infectious viral diseases |
10/22/2002 | US6468553 Extract containing puccoon and chinese angelica |
10/22/2002 | US6468549 Gelling or thickening a cosmetic or dermatological composition |
10/22/2002 | US6468548 Autoclavable pharmaceutical compositions containing a chelating agent |
10/22/2002 | US6468532 Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
10/22/2002 | US6468530 Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
10/22/2002 | US6468527 Biological bioadhesive composition and methods of preparation and use |
10/22/2002 | US6468526 For therapy of vaginal and gastrointestinal infections |
10/22/2002 | US6468522 Derivatives of polymers such as polyethylene glycol containing thiol groups; disulfide linkage with thioamide modifed drug or prodrug; better oral bioavailability and tissue specific targeting |
10/22/2002 | US6468519 Polyanhydrides with biologically active degradation products |
10/22/2002 | US6468507 Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
10/22/2002 | US6468488 Mg-Al anionic clay having 3R2 stacking |